"Herpesvirus 1, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of SIMPLEXVIRUS causing most forms of non-genital herpes simplex in humans. Primary infection occurs mainly in infants and young children and then the virus becomes latent in the dorsal root ganglion. It then is periodically reactivated throughout life causing mostly benign conditions.
| Descriptor ID |
D018259
|
| MeSH Number(s) |
B04.280.382.100.750.390
|
| Concept/Terms |
Herpesvirus 1, Human- Herpesvirus 1, Human
- Herpesvirus 1 (alpha), Human
- Human Herpesvirus 1
- HHV-1
- Herpes Simplex Virus Type 1
- Herpes Simplex Virus 1
- HSV-1
|
Below are MeSH descriptors whose meaning is more general than "Herpesvirus 1, Human".
Below are MeSH descriptors whose meaning is more specific than "Herpesvirus 1, Human".
This graph shows the total number of publications written about "Herpesvirus 1, Human" by people in this website by year, and whether "Herpesvirus 1, Human" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2003 | 1 | 2 | 3 |
| 2004 | 3 | 1 | 4 |
| 2006 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Herpesvirus 1, Human" by people in Profiles.
-
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025 07; 643(8070):219-229.
-
Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023 11; 623(7985):157-166.
-
Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers. Clin Cancer Res. 2022 12 15; 28(24):5419-5430.
-
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540.
-
The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies. Viruses. 2021 06 17; 13(6).
-
Herpes simplex virus-1 KOS-63 strain is virulent and causes titer-dependent corneal nerve damage and keratitis. Sci Rep. 2021 02 19; 11(1):4267.
-
Herpes Simplex Virus 1 MicroRNA miR-H8 Is Dispensable for Latency and Reactivation In Vivo. J Virol. 2021 01 28; 95(4).
-
Deletion of Herpes Simplex Virus 1 MicroRNAs miR-H1 and miR-H6 Impairs Reactivation. J Virol. 2020 07 16; 94(15).
-
Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene. 2019 08; 38(34):6159-6171.
-
Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice. Cancer Gene Ther. 2020 04; 27(3-4):246-255.